This study is designed to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease.

The purpose of this Phase 2a study is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. 

To evaluate the safety and efficacy of an oral investigational medication in people with 

moderately to severely active Crohn’s disease (CD).

To evaluate the safety and efficacy of an oral investigational medication in people with moderately to severely active ulcerative colitis.

This research study is being done to learn more about CLF065 as a potential treatment for chronic pouchitis. The purpose is to learn about the safety of CLF065, and how well a weekly dose of CLF065 treats chronic pouchitis. 

The goal of this study is to asses if MH002 is safe and effective in the treatment of patients with mild to moderate ulcerative colitis who are insufficiently controlled with 5-ASA treatment, and to explore the maintenance of long-term treatment effect. 

Patients and physicians have had questions about the risks of cancer with the use of immune suppressing medications to treat IBD. The goal of this project is to better understand whether people with IBD and diagnosed cancer develop new or recurring cancers, and whether these are correlated with the IBD treatments they receive.

To evaluate whether an investigational treatment called EXE-346, a probiotic biologic drug, may help reduce bowel movement frequency in patients with an ileal pouch-anal anastomosis (IPAA or “j-pouch”). 

The study aims to evaluate if the Investigational study drug (given as pills) can improve signs and symptoms of moderate to severe Crohn’s disease (CD), as well as to see if it has any side effects. 

This platform study will evaluate the efficacy and safety of investigational treatments, including 3 investigational monotherapies and 3 combinations, for adults with moderately to severely active UC.